/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

EDGEWISE THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$22.62 0.0148(1.48%) EWTX at 04 Dec 2025 04:31 PM Biotechnology
Lowest Today 22.53
Highest Today 23.48
Today’s Open 23.28
Prev. Close 22.98
52 Week High 35.50
52 Week Low 10.60
Day’s Range: Low 22.53 High 23.48
52-Week Range: Low 10.60 High 35.50
1 day return -
1 Week return -10.58
1 month return +34.64
3 month return +59.23
6 month return +60.99
1 year return -27.38
3 year return +163.34
5 year return -
10 year return -

Institutional Holdings

Orbimed Advisors, LLC 14.73

RA Capital Management, LLC 9.40

Baker Bros Advisors LP 6.94

BlackRock Inc 6.44

Paradigm Biocapital Advisors LP 5.83

HHG PLC 5.22

Novo A/S 5.08

BRAIDWELL LP 4.95

Vanguard Group Inc 4.60

Perceptive Advisors LLC 4.40

Cormorant Asset Management, LLC 4.04

Siren, L.L.C. 3.00

Vanguard Total Stock Mkt Idx Inv 2.68

Bellevue Group AG 2.64

Driehaus Capital Management LLC 2.00

Deerfield Management Co 1.96

Geode Capital Management, LLC 1.71

State Street Corp 1.69

iShares Russell 2000 ETF 1.67

MPM Oncology Impact Management LP 1.63

First Light Asset Management, LLC 1.63

BB Biotech AG Ord 1.36

Artisan Partners Limited Partnership 1.31

Polar Capital Biotech S Inc 0.93

Artisan International Small-Mid Investor 0.87

Artisan Non-U.S. Small-Mid Growth Comp 0.87

Janus Henderson Global Life Sciences 0.80

Janus Henderson Global Life Sciences D 0.80

Vanguard Institutional Extnd Mkt Idx Tr 0.71

Fidelity Small Cap Index 0.70

Janus Global Life Science AUSD 0.66

Janus Henderson Glb Life Scn I2 USD 0.65

iShares Russell 2000 Growth ETF 0.61

American Century Small Cap Growth Inv 0.58

American Century U.S. Small Cap Growth 0.58

Eventide Healthcare & Life Sciences I 0.54

iShares Biotechnology ETF 0.44

Victory Pioneer Select Mid Cap Growth A 0.39

Janus Henderson Triton D 0.37

Janus Henderson US SMID Cap Growth 0.37

Market Status

Strong Buy: 5

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 2432.86 M

PB Ratio 4.7889

PE Ratio 0.0

Enterprise Value 2116.14 M

Total Assets 486.82 M

Volume 1330779

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-89435000 -89.4M, FY22:-15397000 -15.4M, FY21:-42139000 -42.1M, FY20:-17054000 -17.1M, FY19:-9486000 -9.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-567000 -0.6M, Q1/2025:-554000 -0.6M, Q3/2024:null 0.0M, Q2/2024:-534000 -0.5M

Quarterly Net worth Q3/2025:-40666000 -40.7M, Q2/2025:-36115000 -36.1M, Q1/2025:-40798000 -40.8M, Q3/2024:-34129000 -34.1M, Q2/2024:-31497000 -31.5M

Fund house & investment objective

Company Information Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Organisation Biotechnology

Employees 136

Industry Biotechnology

CEO Dr. Kevin Koch Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow